TLX News

TLX FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The Firm - TLX

Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions

Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX) Over Securities Violations - Contact Levi & Korsinsky Today

Pomerantz LLP Issues Reminder to Shareholders in Telix Pharmaceuticals Limited of Class Action Lawsuit – TLX

Securities Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd. (TLX) - Levi & Korsinsky Represents Shareholders

SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Telix Pharmaceuticals

TLX Deadline: TLX Investors with Losses in Excess of $100K Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm

Levi & Korsinsky Notifies Telix Pharmaceuticals Ltd. (TLX) Shareholders of Class Action Lawsuit and January 9, 2026 Deadline

TLX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Telix Pharmaceuticals Limited Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Telix Pharmaceuticals Ltd. (TLX) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before January 9, 2026